Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8315301 | 1.00 | KMT2A (1.00) | KMT2AKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL954146 | 0.86 | KMT2A (0.76) | KMT2AKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL26054712 | 0.85 | KMT2A (0.74) | KMT2AKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL954303 | 0.85 | KMT2A (0.73) | KMT2AKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL2937795 | 0.85 | KMT2A (0.73) | KMT2AKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL24655998 | 0.82 | MAPK1 (0.74) | KMT2AKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL17321376 | 0.82 | KMT2A (0.69) | KMT2AKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL11267017 | 0.82 | KMT2A (0.69) | KMT2AKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL19675464 | 0.82 | KMT2A (0.69) | KMT2AKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL12789839 | 0.82 | KMT2A (0.69) | KMT2AKDM4EALDH1A1GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269742-B | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amine as therapeutic agents | 常州千红生化制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-2024117980-A1 | COMPOUNDS FOR MODULATING SRC FAMILY KINASES AND USES THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2024-06-06 | — | — | WO | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
| EP-3997088-A1 | DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS | Aucentra Therapeutics Pty Ltd (AU) | 2022-05-18 | — | — | EP | disclosed |
| US-20220002296-A1 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-01-06 | — | — | US | disclosed |
| WO-2020112845-A1 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-06-04 | — | — | WO | disclosed |
| US-10385026-B2 | Phthalazinones and isoquinolinones as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180162823-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-14 | — | — | US | disclosed |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-10 | — | — | US | disclosed |
| EP-1214318-B1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-08 | — | — | EP | disclosed |
| EP-1339699-A1 | SUBSTITUTED AMIDOALKYL URACILS AND THE USE THEREOF | Bayer Aktiengesellschaft (DE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002066480-A2 | 2-ARYLAMINO-PYRIMIDINES FOR THE TREATMENT OF GSK3-RELATED DISORDERS | ASTRAZENECA AB (SE) | 2002-08-29 | — | — | WO | disclosed |
| EP-1214318-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | AstraZeneca AB (SE) | 2002-06-19 | — | — | EP | disclosed |
| WO-2002040455-A1 | SUBSTITUTED AMIDOALKYL URACILS AND THEIR USE AS INHIBITORS OF THE POLY(ADP-RIBOSE) SYNTHETASE (PARS) | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-23 | — | — | WO | disclosed |
| WO-2001014375-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-01 | — | — | WO | disclosed |
| EP-0649425-B1 | PYRIDINO-, PYRROLIDINO- AND AZEPINO-SUBSTITUTED OXIMES USEFUL AS ANTI-ATHEROSCLEROSIS AND ANTI-HYPERCHOLESTEROLEMIC AGENTS | UPJOHN CO (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5597816-A | Pyrazoloazepino substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents | THE UPJOHN COMPANY (US) | 1997-01-28 | — | — | US | disclosed |
| US-5565468-A | 4,5,6,7-TETRAHYDROPYRAZOLO(1,5-A)PYRID-3-YL, PYRAZOLO(1,5-A)PYRID-3-YL, IMIDAZO(1,5-A)PYRIDIN-1-YL OR IMIDAZO(1,2-A)-PYRID-3-YL OXIME DERIVATIVES | THE UPJOHN COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| US-5523318-A | Pyrrolidino-substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents | THE UPJOHN COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | KMT2A 834/4885KDM4E 2073/4885ALDH1A1 4417/4885 |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | KMT2A 1141/4885KDM4E 1029/4885ALDH1A1 2590/4885 |
| US-20180162823-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | KMT2A 1167/4885KDM4E 1119/4885ALDH1A1 2535/4885 |
| US-10385026-B2 | Phthalazinones and isoquinolinones as rock inhibitors | MYLK, MYLK2, ROCK1 | KMT2A 1167/4885KDM4E 1119/4885ALDH1A1 2535/4885 |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | NRAS, KRAS, KSR2 | KMT2A 834/4885KDM4E 2073/4885ALDH1A1 4417/4885 |
| US-20220002296-A1 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | BMI1, GLI1, MCL1 | KMT2A 219/4885KDM4E 343/4885ALDH1A1 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.